See more : Tenpo Innovation CO.,LTD. (3484.T) Income Statement Analysis – Financial Results
Complete financial analysis of PainReform Ltd. (PRFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PainReform Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Mill City Ventures III, Ltd. (MCVT) Income Statement Analysis – Financial Results
- PT. Media Nusantara Citra Tbk (PTMEY) Income Statement Analysis – Financial Results
- AURES Technologies S.A. (AURS.PA) Income Statement Analysis – Financial Results
- Fujian Sanmu Group Co., Ltd. (000632.SZ) Income Statement Analysis – Financial Results
- Tesla, Inc. (TSLA.NE) Income Statement Analysis – Financial Results
PainReform Ltd. (PRFX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.painreform.com
About PainReform Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 15.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 |
| Gross Profit | -15.00K | 71.00K | -7.00K | 0.00 | -1.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 82.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.04M | 4.42M | 2.86M | 354.00K | 136.00K | 223.00K | 504.00K |
| General & Administrative | 3.48M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
| Selling & Marketing | 66.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.55M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
| Cost & Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
| Interest Income | 406.00K | 160.00K | 0.00 | 1.05K | 588.00 | 0.00 | 245.00K |
| Interest Expense | 384.00K | 61.00K | 10.00K | 987.00K | 541.00K | 324.00K | 0.00 |
| Depreciation & Amortization | 15.00K | 15.00K | 7.00K | 1.00K | 1.00K | 500.00K | 880.00K |
| EBITDA | -9.57M | -8.85M | -7.20M | -1.67M | -688.00K | 0.00 | -1.21M |
| EBITDA Ratio | 0.00% | -10,124.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.58M | -8.87M | -7.21M | -1.67M | -689.00K | -500.00K | -880.00K |
| Operating Income Ratio | 0.00% | -10,312.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 248.00K | 86.00K | -32.00K | -2.16M | -590.00K | -328.00K | -242.00K |
| Income Before Tax | -9.34M | -8.78M | -7.24M | -3.83M | -1.28M | -828.00K | -1.12M |
| Income Before Tax Ratio | 0.00% | -10,212.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 8.00K | 9.00K | 6.00K | 220.00K | 541.00K | 4.00K | -242.00K |
| Net Income | -9.34M | -8.79M | -7.25M | -4.05M | -1.82M | -828.00K | -2.09M |
| Net Income Ratio | 0.00% | -10,223.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -42.86 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.67 |
| EPS Diluted | -42.83 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.25 |
| Weighted Avg Shares Out | 218.00K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.00K |
| Weighted Avg Shares Out (Dil) | 218.15K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.66K |
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will...
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th
TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference,...
PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today
PainReform (PRFX) stock is on the move Monday with heavy trading despite a lack of news coming from the medical device company. The post PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today...
PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
TEL AVIV, Israel, Oct. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will...
Highest Volume Penny Stocks to Watch Today? Check These 4 Out
Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?
PRFX Stock Increases Over 60% Pre-Market: Details You Should Know
The stock price of PainReform Ltd (NASDAQ: PRFX) increased by over 60% pre-market. These are some details you should know.
PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading
We're seeing lots of activity from penny stock PainReform (PRFX) on Wednesday despite a lack of news from the pharmaceutical company. The post PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading appeared first on InvestorPlace.
PainReform Provides Business Update for the First Quarter of 2021
Reports continued progress towards start of Phase 3 trials Reports continued progress towards start of Phase 3 trials
PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
HERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, CEO of PainReform, has been invited...
PainReform Announces $6.0 Million Private Placement
HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into securities purchase agreements with...
Source: https://incomestatements.info
Category: Stock Reports